BioCardia, Inc. (BCDA)
NASDAQ$2.8
Market Cap
$13.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
296 of 918
Rank in Industry
171 of 522
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BCDA Insider Trading Activity
BCDA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $99,966 | 10 | 91 |
Sells | $6,514 | 1 | 9 |
Related Transactions
| STERTZER SIMON H | director | 3 | $90,515 | 0 | $0 | $90,515 |
| Altman Peter | President and CEO | 7 | $9,451 | 0 | $0 | $9,451 |
| GILLIS EDWARD M | Senior Vice President, Devices | 0 | $0 | 1 | $6,514 | $-6,514 |
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the …
Insider Activity of BioCardia, Inc.
Over the last 12 months, insiders at BioCardia, Inc. have bought $99,966 and sold $6,514 worth of BioCardia, Inc. stock.
On average, over the past 5 years, insiders at BioCardia, Inc. have bought $408,708 and sold $31,164 worth of stock each year.
Highest buying activity among insiders over the last 12 months: STERTZER SIMON H (director) — $90,515. Altman Peter (President and CEO) — $9,451.
The last purchase of 1,000 shares for transaction amount of $2,450 was made by STERTZER SIMON H (director) on 2025‑03‑05.
List of Insider Buy and Sell Transactions, BioCardia, Inc.
| 2025-03-05 | STERTZER SIMON H | director | 1,000 0.0211% | $2.45 | $2,450 | +2.36% | ||
| 2025-03-04 | STERTZER SIMON H | director | 15,536 0.3105% | $2.30 | $35,733 | +3.17% | ||
| 2025-03-03 | Altman Peter | President and CEO | 500 0.009% | $2.11 | $1,055 | +2.77% | ||
| 2025-03-03 | STERTZER SIMON H | director | 22,753 0.4459% | $2.30 | $52,332 | +2.77% | ||
| 2025-02-07 | Altman Peter | President and CEO | 600 0.0132% | $2.48 | $1,488 | +8.65% | ||
| 2025-01-30 | Altman Peter | President and CEO | 239 0.0052% | $2.38 | $569 | +10.56% | ||
| 2025-01-29 | Altman Peter | President and CEO | 500 0.0115% | $2.40 | $1,200 | +7.56% | ||
| 2024-12-23 | Altman Peter | President and CEO | 1,000 0.0218% | $2.06 | $2,060 | +20.65% | ||
| 2024-12-20 | Sale | GILLIS EDWARD M | Senior Vice President, Devices | 3,257 0.0712% | $2.00 | $6,514 | +22.34% | |
| 2024-12-05 | Altman Peter | President and CEO | 250 0.0056% | $2.22 | $555 | +7.64% | ||
| 2024-11-15 | Altman Peter | President and CEO | 1,350 0.034% | $1.87 | $2,525 | +24.86% | ||
| 2024-01-19 | Sale | FROST PHILLIP MD ET AL | 10 percent owner | 129,802 0.5902% | $0.43 | $55,815 | -54.42% | |
| 2023-08-17 | Altman Peter | President and CEO | 4,000 0.0199% | $0.87 | $3,484 | -82.61% | ||
| 2023-08-14 | Altman Peter | President and CEO | 4,500 0.022% | $0.88 | $3,978 | -83.28% | ||
| 2023-05-26 | Altman Peter | President and CEO | 6,200 0.0264% | $1.60 | $9,920 | -87.76% | ||
| 2022-12-16 | FROST PHILLIP MD ET AL | director | 595,238 3.3% | $1.68 | $1,000,000 | +9.94% | ||
| 2022-11-11 | Altman Peter | President and CEO | 1,400 0.0079% | $1.86 | $2,604 | +1.89% | ||
| 2022-11-10 | Altman Peter | President and CEO | 3,100 0.0176% | $1.87 | $5,797 | +1.08% | ||
| 2022-10-10 | McClung David | Chief Financial Officer | 2,000 0.0112% | $2.07 | $4,140 | -4.75% | ||
| 2022-09-23 | Altman Peter | President and CEO | 1,400 0.0079% | $1.87 | $2,618 | +6.99% |
Total: 158
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Altman Peter | President and CEO | 108420 2.3167% | $303,576.00 | 68 | 0 | <0.0001% |
| STERTZER SIMON H | director | 57138 1.2209% | $159,986.40 | 21 | 0 | +44.98% |
| Brooks Andrew A | CEO | 63560031 1358.1174% | $177.97M | 11 | 0 | |
| BROOKS JONATHAN | director, 10 percent owner | 32045292 684.727% | $89.73M | 1 | 2 | |
| FROST PHILLIP MD ET AL | 10 percent owner | 1896025 40.5133% | $5.31M | 19 | 2 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $12.78M | |
$1,724,269 | 63 | -16.36% | $12.53M | |
$8,900,811 | 57 | -24.79% | $13.36M | |
$85,897,100 | 36 | 2.47% | $14.08M | |
$95,303,339 | 30 | -13.78% | $12.66M |
BCDA Institutional Investors: Active Positions
| Increased Positions | 6 | +60% | 50,901 | +50.16% |
| Decreased Positions | 3 | -30% | 27,534 | -27.13% |
| New Positions | 4 | New | 30,664 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 13 | +30% | 124,849 | +23.03% |
BCDA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Susquehanna International Group, Llp | $117.00 | 0.88% | 43,842 | -26,754 | -37.9% | 2024-12-31 |
| Geode Capital Management, Llc | $82.00 | 0.62% | 30,987 | +16,251 | +110.28% | 2024-12-31 |
| Cm Management, Llc | $67.00 | 0.5% | 25,000 | +25,000 | New | 2024-12-31 |
| Vanguard Group Inc | $34.00 | 0.26% | 12,884 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $13.00 | 0.1% | 4,750 | +4,750 | New | 2024-12-31 |
| Morgan Stanley | $11.00 | 0.08% | 4,016 | +3,986 | +13,286.67% | 2024-12-31 |
| Pingora Partners Llc | $3.00 | 0.02% | 1,036 | 0 | 0% | 2024-12-31 |
| Jpmorgan Chase & Co | $2.00 | 0.02% | 899 | +899 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 535 | -747 | -58.27% | 2024-12-31 |
| Bank Of America Corp /De/ | $1.00 | 0.01% | 413 | -33 | -7.4% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.